Alendronate in the prevention of osteoporosis: 7-year follow-up

Osteoporosis International

Volumn 15, Issue 6, 2004, Pages 483-488

  Sambrook, P N ^a   Rodriguez, J P ^b   Wasnich, R D ^c   Luckey, M M ^d   Kaur, A ^e   Meng, L ^e   Lombardi, A ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CHILE   (Chile)

^c Hawaii Osteoporosis Center   (United States)

^d Saint Barnabas Ambulatory Care Ctr   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Osteoporosis; Postmenopausal women; Spine

Indexed keywords

ALENDRONIC ACID; PLACEBO;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; FEMUR NECK; FOLLOW UP; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; OSTEOLYSIS; OSTEOPOROSIS; PEPTIC ULCER; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SPINE; TREATMENT OUTCOME;

EID: 3042689740     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-003-1571-4     Document Type: Article

References (17)

1. Riggs BL, Melton LJ (1992) The prevention and treatment of osteoporosis. N Engl J Med 327:620-627
2. America's bone health (2002) The state of osteoporosis and low bone mass in our nation. National Osteoporosis Foundation
3. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of alendronate on risk of fractures in women with existing vertebral fractures. Lancet 348:1535-1541
5. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Adami S, Harris ST, Santora AC, Hirsch LJ, Oppenheimer L, Thompson D (1997) Prevention of nonvertebral fractures by alendronate. J Am Med Assoc 277:1159-1164
6. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. J Am Med Assoc 280:2077-2082
7. Pols HAP, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study, Osteoporos Int 9:461-468
8. Bell NH, Bilezikian JP, Bone HG, Kaur A, Maragoto A, Santora AC (2002) Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 87:2792-2797
9. Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Baslke A, Thompson D, Daley M, Yates AJ (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485-492
10. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, El Haji Fuleihan G, Reda C, Yates AJ, Ravn P (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med 128:253-261
11. Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, AJ Yates, Daifotis A, El-Haji Fuleihan G. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal
12. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85:3109-3115
13. Writing group for the women's health initiative investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 288:321-333
14. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. J Am Med Assoc 289:2651-2662
15. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR (2002) Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 87:4914-4923
16. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann Intern Med 137:875-883
17. Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BGA, Magaril CH, Vandormael K, Stych B, Melton ME (2003) Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy. Arch Intern Med 163:789-794